Inhibition of Growth of LCI D20 Hepatocellular Carcinoma by Endostatin

Zhao‐You Tang
1999-01-01
Abstract:Objective To evaluate the inhibitory effect of endostatin on the growth of LCI D20, a highly metastatic hepatocellular carcinoma. Methods Thirty nude mice were subcutaneously implanted with LCI D20 tumor tissues, then treated with subcutaneous injection of 2 mg·kg -1 ·d -1 (group EA) or 4 mg·kg -1 ·d -1 (group EB) Endostatin, or intraperitoneal injection of 1 mg·kg -1 ·d -1 cis-platin (group C), or 4 mg·kg -1 ·d -1 plus 1 mg·kg -1 ·d -1 cis-platin (group EC), or subcutaneous injection of 0.2 mg/d PBS as control. All treatment lasted 40 days after implantation. The tumor size was calculated by using the formula: V=L×W 2×0.52. Results The mean tumor size of each group was (8376±2129) mm 3 for the control, (6095±2261) mm 3 for group EA, (3777±2042) mm 3 for group EB, (1629±877) mm 3 for group C, and (1248±847) mm 3 for group EC, when measured on the day 40 after implantation. Statistical analysis showed that 2 mg·kg -1 ·d -1 Endostatin had no inhibitory effect on the growth of LCI D20, however, 4 mg·kg -1 ·d -1 Endostatin, 1 mg·kg -1 ·d -1 cis-platin and combination of these two drugs delayed the growth of LCI D20. Combination treatment increased the inhibitory effect on the tumor growth, as compared with Endostatin alone. Conclusion Antiangiogenic therapy inhibited the growth of hepatocellular carcinoma. Combination treatment improved the inhibitory effect.\;
What problem does this paper attempt to address?